



Piercarlo Saletti

Contact

Piercarlo Saletti

Publications (8)

Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. *J Geriatr Oncol* 2018; 10:304-310.

von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). *Eur J Cancer* 2017; 89:82-89.

Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Köberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. *Oncology* 2011; 81:50-4.

Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3702-8.

Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tamas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3695-701.

Hess V, Scheithauer W, Figer A, Saletti P, Bajetta E, Ruhstaller T, Bodoky G, Dietrich D, Grawe P, Glimelius B, Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. *The lancet oncology* 2008; 9:132-8.

Roth A, de Braud F, Seymour M, Widmer L, Glynn-Jones R, Leslie M, Wernli M, Maibach R, Rufibach K, Borner M, Köberle D, Saletti P, Bernhard J, Falk S, Stupp R, Fazio N, Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007; 25:3217-23.

Herrmann R, Stemmer S, Tamas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007; 25:2212-7.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch